Why talk to a hematologist about mast cell disease and systemic mastocytosis treatment?

Dr. Douglas Tremblay, a leading hematologist, joins Dr. G and Kortney to discuss the role of a hematologist-oncologist in diagnosing and treating mastocytosis. We discuss bone marrow's vital role in diagnosing and treating systemic mastocytosis. 

Dr. Tremblay discusses the latest KIT inhibitors, a promising group of medications, and explains the difference between indolent and advanced systemic mastocytosis. He clarifies how KIT inhibitors work and emphasizes the importance of managing side effects. Finally, Dr. Tremblay provides insights into the future of KIT inhibitor approval and explores the possibility of participating in a clinical trial for Bezulastinib. 

What we cover in this episode about treating systemic mastocytosis:

• What is a hematologist looking at with mast cell disease patients?

• Bone marrow biopsy for systemic mastocytosis 

• Avapritinib

Dr. Tremblay: https://profiles.mountsinai.org/douglas-a-tremblay

Dr. Tremblay’s email: [email protected] 

Mast Cell Disease Overview: https://allergyasthmanetwork.org/health-a-z/mast-cell-diseases/

What is Anaphylaxis? https://allergyasthmanetwork.org/anaphylaxis/

What is Epinephrine? https://allergyasthmanetwork.org/anaphylaxis/what-is-epinephrine/

The Mast Cell Disease Society: https://tmsforacure.org/

Current studies enrolling patients: https://tmsforacure.org/clinical-trials/